Lentiviral human APPL1 sgRNA gene knockout kit

Lentiviral human APPL1 sgRNA gene knockout kit

Catalog Number:
CGKK546778FEN
Mfr. No.:
HKO-610532
Price:
$878
  • Size:
    Quantity:
    Add to Cart:
      • Overview
        • Kit Components: Lentiviral particles or plasmids for a set of three sgRNAs, and a pair of Indel screening PCR primers

          sgRNA lentiviral particle information
          • Functional titer: 1x10^8 TU/ml
          • Titration method: counting puromycin resistant cell clones
          • Purity: In vivo grade
          • Pseudotype: VSVG
          • Storage buffer: LentiShield™ lentivirus storage buffer
          • Storage: condition -80°C
          • Availability: 3-5 weeks

          sgRNA lentiviral plasmid information
          • Promoter for target sgRNA: U6
          • Mammalian selection: puromycin
          • Promoter for mammalian selection gene: EF1a
          • E.coli selection: Amp
          • Storage condition: -20°C
          • Availability: 1-2 weeks

          Please contact us at for specific academic pricing.

          Target Information

          Target Name
          Human APPL1
          About Target
          Gene symbol: APPL1
          Synonyms: APPL DIP13alpha MODY14
          Species: HUMAN
          Gene ID: 26060
          Summary: The protein encoded by this gene has been shown to be involved in the regulation of cell proliferation, and in the crosstalk between the adiponectin signalling and insulin signalling pathways. The encoded protein binds many other proteins, including RAB5A, DCC, AKT2, PIK3CA, adiponectin receptors, and proteins of the NuRD/MeCP1 complex. This protein is found associated with endosomal membranes, but can be released by EGF and translocated to the nucleus. [provided by RefSeq, Jul 2008].
          NM numbers targeted (Accession number:Exon:CDS Fragment): NM_012096:10:10
      • Properties
        • * For Research Use Only.

    Note: If you don't receive our verification email, do the following:

    Copyright © Amerigo Scientific. All rights reserved.